Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 130Recurrence 34Lymphoma, Follicular 28Lymphoma, Large B-Cell, Diffuse 27Lymphoma, Non-Hodgkin 23Neoplasms 13Lymphoma 13Lymphoma, Mantle-Cell 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Lymphocytic, Chronic, B-Cell 11Hematologic Diseases 5Neoplasms, Plasma Cell 4Myelodysplastic Syndromes 4Lymphoma, B-Cell 4Hematologic Neoplasms 4Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Acute 3Pyloric Stenosis, Hypertrophic 2Prostatic Neoplasms 2Paraproteinemias 2Ovarian Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, T-Cell, Peripheral 2Leukemia-Lymphoma, Adult T-Cell 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Bortezomib 3ricolinostat 1pomalidomide 1ficlatuzumab 1Zoledronic Acid 1Vorinostat 1Lenalidomide 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Dexamethasone 1Denosumab 1CLR1404 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Blood Protein Disorders × Lenalidomide × Clear all
NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Celgene

Phase 3 Withdrawn
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡